Ritter Daniher Financial Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$127K Sell
255
-27
-10% -$12K 0.02% 203
2026
Q1
$126K Hold
282
0.02% 201
2025
Q4
$128K Hold
282
0.02% 198
2025
Q3
$110K Hold
282
0.02% 188
2025
Q2
$126K Hold
282
0.03% 115
2025
Q1
$137K Sell
282
-15
-5% -$6.99K 0.04% 103
2024
Q4
$120K Sell
297
-29
-9% -$13.4K 0.03% 107
2024
Q3
$152K Hold
326
0.04% 95
2024
Q2
$153K Hold
326
0.05% 87
2024
Q1
$136K Sell
326
-78
-19% -$33K 0.05% 99
2023
Q4
$164K Sell
404
-46
-10% -$17K 0.06% 82
2023
Q3
$156K Buy
450
+184
+69% +$64.4K 0.07% 78
2023
Q2
$93.6K Hold
266
0.04% 105
2023
Q1
$83.8K Hold
266
0.04% 107
2022
Q4
$76.8K Buy
+266
New +$81.1K 0.04% 115

Other funds holding VRTX

Ritter Daniher Financial Advisory's VRTX Position: Q2 2026 in Review

Ritter Daniher Financial Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 9.6% in Q2 2026, selling an estimated $12K and leaving 255 shares worth $127K. The position accounts for 0.02% of the portfolio, ranked #203.

Ritter Daniher Financial Advisory first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $164K in Q4 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ritter Daniher Financial Advisory held 255 shares of Vertex Pharmaceuticals worth $127K as of Q2 2026.
  • Ritter Daniher Financial Advisory sold 27 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12K.
  • Vertex Pharmaceuticals made up 0.02% of Ritter Daniher Financial Advisory's portfolio in Q2 2026, its #203 holding.
  • Ritter Daniher Financial Advisory first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Ritter Daniher Financial Advisory's Vertex Pharmaceuticals position peaked at $164K in Q4 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ritter Daniher Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.